PMID- 25483516
OWN - NLM
STAT- MEDLINE
DCOM- 20151230
LR  - 20181113
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 11
IP  - 1
DP  - 2015
TI  - Normal or defective immune response to Hepatitis B vaccine in patients with 
      diabetes and celiac disease.
PG  - 58-62
LID - 10.4161/hv.34309 [doi]
AB  - A defective production of protective levels of antibodies to Hepatitis B (HB) 
      vaccine is reported to occur in 4-10% of healthy subjects and a correlation with 
      the presence of specific human leukocyte antigen (HLA) molecules, including DQ2, 
      which also confers genetic predisposition to celiac disease (CD) and type I 
      diabetes mellitus (T1DM), has been suggested.   The aim of this study was to 
      analyze the serological response to HB vaccine and measles-containing vaccines in 
      69 diabetic patients (T1DM), 42 patients with celiac disease (CD) and 79 healthy 
      control subjects (CT). The median interval between the third dose of HB vaccine 
      and serum collection was 6.8, 3.5, and 4.7 years for T1DM, CD and CT groups, 
      respectively. 50/69 (72%) T1DM patients, 32/42 (76%) CD patients and 61/79 (77%) 
      CT subjects showed protective anti-HBs antibodies after vaccination, with no 
      statistically significant difference. On the contrary, a lower statistically 
      significant difference was found in the mean HBsAb level of T1DM subjects when 
      compared with the other two groups. No correlation between HLA DQ2 expression in 
      T1DM and vaccine response was detected. The comparison of serological response to 
      measles after vaccination also showed no statistically significant differences in 
      the three groups. Contrasting results between these data and those reported in 
      the literature might be due to differences in the time intervals between 
      vaccination and testing. Prospective studies in pathological and healthy groups 
      with the same age at HBV vaccination and with the same time interval for blood 
      sample collection to determine antibody titers are necessary in order to provide 
      more conclusive data.
FAU - Zanoni, Giovanna
AU  - Zanoni G
AD  - a Department of Pathology and Diagnostics; Section of Immunology; University of 
      Verona; Italy.
FAU - Contreas, Giovanna
AU  - Contreas G
FAU - Valletta, Enrico
AU  - Valletta E
FAU - Gabrielli, Oretta
AU  - Gabrielli O
FAU - Mengoli, Carlo
AU  - Mengoli C
FAU - Veneri, Dino
AU  - Veneri D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141101
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Measles Vaccine)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Viral/*blood
MH  - Celiac Disease/*immunology
MH  - Child
MH  - Child, Preschool
MH  - Diabetes Mellitus, Type 1/*immunology
MH  - Female
MH  - HLA-DQ Antigens/genetics
MH  - Hepatitis B Vaccines/administration & dosage/*immunology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Measles Vaccine/administration & dosage/*immunology
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC4514307
OTO - NOTNLM
OT  - HBsAb
OT  - HLA DQ2
OT  - celiac disease
OT  - hepatitis B
OT  - measles
OT  - type 1 diabetes mellitus
OT  - vaccination
EDAT- 2014/12/09 06:00
MHDA- 2015/12/31 06:00
PMCR- 2015/08/06
CRDT- 2014/12/09 06:00
PHST- 2014/12/09 06:00 [entrez]
PHST- 2014/12/09 06:00 [pubmed]
PHST- 2015/12/31 06:00 [medline]
PHST- 2015/08/06 00:00 [pmc-release]
AID - 984110 [pii]
AID - 10.4161/hv.34309 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2015;11(1):58-62. doi: 10.4161/hv.34309. Epub 2014 Nov 1.